Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 17, 2020

Celltex to study mesenchymal stem cells for coronavirus treatment

Celltex Therapeutics has initiated talks with the US Food and Drug Administration (FDA) to conduct a study of adult, autologous mesenchymal stem cells (MSCs) for the treatment of Covid-19 symptoms.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.

Celltex Therapeutics has initiated talks with the US Food and Drug Administration (FDA) to conduct a study of adult, autologous mesenchymal stem cells (MSCs) for the treatment of Covid-19 symptoms.

The company assessed the safety and efficacy of MSCs in people with injuries, pain and conditions associated with autoimmune, vascular and other diseases such as pneumonia.

Celltex, in alliance with the Texas A&M University Institute for Regenerative Medicine, evaluated MSCs in Covid-19 patients. Data from this study showed that intravenous administration of clinical-grade human MSCs led to improved functional outcomes.

The editorial titled ‘Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (Covid-19) – Induced Pneumonia’ was published in the Aging and Disease journal.

During the study, intravenous MSCs were found to be safe and effective in treating novel coronavirus patients with pneumonia. The therapy is said to have yielded encouraging data even in elderly patients with severe pneumonia.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU